BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $100.00 price target on Disc Medicine (NASDAQ: IRON)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
